SAN MATEO, Calif.--(BUSINESS WIRE)--Epocrates, Inc. (NASDAQ:EPOC), a leading provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry, today announced the effectiveness of the appointment of Peter C. Brandt to its board of directors. Brandt has extensive experience in leading financial, organizational and operational initiatives with top pharmaceutical companies. As a member of the Epocrates board, Brandt is expected to work closely with company leadership to guide the strategic direction of its interactive services for the healthcare industry. Brandt will also become a member of the board’s audit and compensation committees.
“Peter is a tremendous addition to the Epocrates board of directors. His expertise and perspective will provide the company with a fresh outlook,” said Rose Crane, president and chief executive officer for Epocrates. “Peter is respected by the pharmaceutical community, and can be described as both an industry veteran and an innovative entrepreneur.”
“I am honored to join the board and hope to help Epocrates continue its legacy of providing medical professionals with valuable solutions at the point of care, especially at such an exciting time for both the company and the industry,” said Brandt.
For more than twenty years, Brandt held leadership positions with Pfizer, Inc., ultimately serving as president of Pfizer’s U.S. Pharmaceuticals Operations. During his tenure, Brandt significantly grew the company’s revenue and Latin American business. He was also at the helm of Pfizer Health Solutions, a subsidiary that provided technology-based clinical solutions for patients, physicians and healthcare organizations.
Most recently, Brandt was the president and chief executive officer of Noven Pharmaceuticals, Inc., developer of a transdermal drug delivery system. Noven Pharmaceuticals, a publicly-held company, was acquired by Japanese drug-maker Hisamitsu Pharmaceutical in 2009. Brandt also currently serves on the board of directors for Auxilium Pharmaceuticals, Inc. and Rexahn Pharmaceuticals, Inc.
Epocrates (NASDAQ: EPOC) is a leading provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry. Epocrates’ active user network currently has more than one million healthcare professionals, including more than 45 percent of U.S. physicians. Most commonly used on mobile devices at the point of care, the company’s clinical products and services help healthcare professionals make more informed prescribing decisions, enhance patient safety and improve practice productivity. For more information about Epocrates, please visit www.epocrates.com/company.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the company’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, risks detailed in Epocrates’ filings with, the Securities and Exchange Commission (SEC), including in Epocrates’ registration statement on Form S-1 filed with the SEC on July 15, 2010, as amended. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Epocrates does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6596949&lang=en